Search research articles
Contact Us
Filters
Showing results (41-50 of 69) with videos related to
Page
of 7
Sort By:
Archives of Dermatological Research
|
December 24, 2013
Topical application of the synthetic triterpenoid RTA 408 activates Nrf2 and induces cytoprotective genes in rat skin
Scott A Reisman, Chun-Yue I Lee, Colin J Meyer, et al.
Clinical Ophthalmology (Auckland, N.Z.)
|
May 17, 2018
The development of a reference database with the Topcon 3D OCT-1 Maestro
Michael Chaglasian, Murray Fingeret, Pinakin Gunvant Davey, et al.
The American Journal of Medicine
|
October 1, 1980
Association of monocytic leukemia in patients with extreme leukocytosis
J Cuttner, M S Conjalka, M Reilly, et al.
Journal of the American Society of Nephrology : JASN
|
August 4, 2012
Bardoxolone methyl decreases megalin and activates nrf2 in the kidney
Scott A Reisman, Glenn M Chertow, Sudarshan Hebbar, et al.
Drug Design, Development and Therapy
|
May 24, 2019
Pharmacokinetics and pharmacodynamics of the novel Nrf2 activator omaveloxolone in primates
Scott A Reisman, Sarabjit S Gahir, Chun-Yue I Lee, et al.
Redox Biology
|
December 24, 2013
The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores endothelial function impaired by reduced Nrf2 activity in chronic kidney disease
Mohammad A Aminzadeh, Scott A Reisman, Nosratola D Vaziri, et al.
Toxicology and Applied Pharmacology
|
July 12, 2008
Coordinated induction of Nrf2 target genes protects against iron nitrilotriacetate (FeNTA)-induced nephrotoxicity
Yuji Tanaka, Lauren M Aleksunes, Michael J Goedken, et al.
Radiation Research
|
April 12, 2014
Topical application of the synthetic triterpenoid RTA 408 protects mice from radiation-induced dermatitis
Scott A Reisman, Chun-Yue I Lee, Colin J Meyer, et al.
Journal of Lower Genital Tract Disease
|
July 2, 2014
Metronidazole vaginal gel 1.3% in the treatment of bacterial vaginosis: a dose-ranging study
Steven E Chavoustie, Mark Jacobs, Howard A Reisman, et al.
Investigational New Drugs
|
January 1, 1985
Phase I-II trial of mitoxantrone in acute leukemia: an interim report
Z A Arlin, G Dukart, I Schoch, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 69) with videos related to
Sort By:
Page
of 7
Archives of Dermatological Research
|
December 24, 2013
Topical application of the synthetic triterpenoid RTA 408 activates Nrf2 and induces cytoprotective genes in rat skin
Scott A Reisman, Chun-Yue I Lee, Colin J Meyer, et al.
Clinical Ophthalmology (Auckland, N.Z.)
|
May 17, 2018
The development of a reference database with the Topcon 3D OCT-1 Maestro
Michael Chaglasian, Murray Fingeret, Pinakin Gunvant Davey, et al.
The American Journal of Medicine
|
October 1, 1980
Association of monocytic leukemia in patients with extreme leukocytosis
J Cuttner, M S Conjalka, M Reilly, et al.
Journal of the American Society of Nephrology : JASN
|
August 4, 2012
Bardoxolone methyl decreases megalin and activates nrf2 in the kidney
Scott A Reisman, Glenn M Chertow, Sudarshan Hebbar, et al.
Drug Design, Development and Therapy
|
May 24, 2019
Pharmacokinetics and pharmacodynamics of the novel Nrf2 activator omaveloxolone in primates
Scott A Reisman, Sarabjit S Gahir, Chun-Yue I Lee, et al.
Redox Biology
|
December 24, 2013
The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores endothelial function impaired by reduced Nrf2 activity in chronic kidney disease
Mohammad A Aminzadeh, Scott A Reisman, Nosratola D Vaziri, et al.
Toxicology and Applied Pharmacology
|
July 12, 2008
Coordinated induction of Nrf2 target genes protects against iron nitrilotriacetate (FeNTA)-induced nephrotoxicity
Yuji Tanaka, Lauren M Aleksunes, Michael J Goedken, et al.
Radiation Research
|
April 12, 2014
Topical application of the synthetic triterpenoid RTA 408 protects mice from radiation-induced dermatitis
Scott A Reisman, Chun-Yue I Lee, Colin J Meyer, et al.
Journal of Lower Genital Tract Disease
|
July 2, 2014
Metronidazole vaginal gel 1.3% in the treatment of bacterial vaginosis: a dose-ranging study
Steven E Chavoustie, Mark Jacobs, Howard A Reisman, et al.
Investigational New Drugs
|
January 1, 1985
Phase I-II trial of mitoxantrone in acute leukemia: an interim report
Z A Arlin, G Dukart, I Schoch, et al.
Page
of 7